308 related articles for article (PubMed ID: 32002673)
1. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.
Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U
Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673
[TBL] [Abstract][Full Text] [Related]
2. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia.
Jentzsch M; Schwind S; Bach E; Stasik S; Thiede C; Platzbecker U
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652787
[TBL] [Abstract][Full Text] [Related]
3. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K; Stock W; Walter RB
Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
[TBL] [Abstract][Full Text] [Related]
4. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS; Ommen HB
Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
[TBL] [Abstract][Full Text] [Related]
5. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
6. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
Shah MV; Jorgensen JL; Saliba RM; Wang SA; Alousi AM; Andersson BS; Bashir Q; Ciurea SO; Kebriaei P; Marin D; Patel KP; Popat UR; Rezvani K; Rondon G; Shpall EJ; Champlin RE; Oran B
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1514-1520. PubMed ID: 29448058
[TBL] [Abstract][Full Text] [Related]
7. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
8. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
9. Widespread use of measurable residual disease in acute myeloid leukemia practice.
Epstein-Peterson ZD; Devlin SM; Stein EM; Estey E; Tallman MS
Leuk Res; 2018 Apr; 67():92-98. PubMed ID: 29482173
[TBL] [Abstract][Full Text] [Related]
10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
11. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
[TBL] [Abstract][Full Text] [Related]
12. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
13. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
14. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
Fasan O
Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
[TBL] [Abstract][Full Text] [Related]
15. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
16. Expanded activated autologous lymphocyte infusions improve outcomes of low- and intermediate-risk childhood acute myeloid leukemia with low level of minimal residual disease.
Zhang LP; Lu AD; Wu J; Jia YP; Zuo YX; Zhang YH; Zhao YH; Shang W; Xie DF; Li YC; Sun Z; Ma SQ
Cancer Lett; 2020 Nov; 493():128-132. PubMed ID: 32829005
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease testing in acute myeloid leukaemia.
Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
